Trial Outcomes & Findings for A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (NCT NCT02998528)

NCT ID: NCT02998528

Last Updated: 2026-01-06

Results Overview

Event-free survival (EFS) is defined as the length of time from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on blinded independent central review (BICR) assessment per response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 505 participants
• Primary outcome timeframe: From randomization to disease progression, reoccurrence, or death due to any cause. (Up to a median of 30 months)
• Results posted on: 2026-01-06

Participant Flow

One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm A for baseline and efficacy analyses (analyses based on the randomized population) and is counted in Arm B (chemo) for exposure and safety analyses (based on the treated population). This participant was randomized prior to Revised Protocol 02 and is not included in the All Treated Participants from the Concurrently Randomized Arms B and C population.

Participant milestones

Measure	Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg Participants received nivolumab 3 mg/kg IV over 30 minutes every 2 weeks for up to 3 doses (ie, 6 weeks of treatment; each cycle is 14 days). In Cycle 1 Day 1 only, nivolumab will be followed by a single dose of ipilimumab 1 mg/kg IV over 30 minutes. Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm B: Platinum Doublet Chemo Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm C: Nivo 360 mg + Platinum Doublet Chemo Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
Randomization Period STARTED	113	213	179
Randomization Period All Concurrently Randomized Participants in Arms B and C	0	179	179
Randomization Period COMPLETED	112	207	176
Randomization Period NOT COMPLETED	1	6	3
Neoadjuvant Treatment Period STARTED	111	208	176
Neoadjuvant Treatment Period All Treated Participants From Concurrently Randomized Arms B and C	0	176	176
Neoadjuvant Treatment Period COMPLETED	101	177	165
Neoadjuvant Treatment Period NOT COMPLETED	10	31	11
Systemic Adjuvant Treatment Period STARTED	37	47	26
Systemic Adjuvant Treatment Period COMPLETED	28	41	22
Systemic Adjuvant Treatment Period NOT COMPLETED	9	6	4

Reasons for withdrawal

Measure	Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg Participants received nivolumab 3 mg/kg IV over 30 minutes every 2 weeks for up to 3 doses (ie, 6 weeks of treatment; each cycle is 14 days). In Cycle 1 Day 1 only, nivolumab will be followed by a single dose of ipilimumab 1 mg/kg IV over 30 minutes. Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm B: Platinum Doublet Chemo Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm C: Nivo 360 mg + Platinum Doublet Chemo Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
Randomization Period Adverse event unrelated to study drug	0	0	1
Randomization Period Participant withdrew consent	0	3	0
Randomization Period Participant no longer meets study criteria	1	3	2
Neoadjuvant Treatment Period Participant request to discontinue study treatment	0	7	0
Neoadjuvant Treatment Period Participant withdrew consent	0	4	0
Neoadjuvant Treatment Period Participant no longer meets study criteria	0	1	0
Neoadjuvant Treatment Period Disease progression	3	2	1
Neoadjuvant Treatment Period Study drug toxicity	6	14	10
Neoadjuvant Treatment Period Death	1	0	0
Neoadjuvant Treatment Period Adverse event unrelated to study treatment	0	3	0
Systemic Adjuvant Treatment Period Disease progression	1	0	0
Systemic Adjuvant Treatment Period Study drug toxicity	4	5	1
Systemic Adjuvant Treatment Period Adverse event unrelated to study drug	1	0	1
Systemic Adjuvant Treatment Period Participant request to discontinue treatment	3	1	1
Systemic Adjuvant Treatment Period Other reasons	0	0	1

Baseline Characteristics

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Baseline characteristics by cohort

Measure	Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg n=113 Participants Participants received nivolumab 3 mg/kg IV over 30 minutes every 2 weeks for up to 3 doses (ie, 6 weeks of treatment; each cycle is 14 days). In Cycle 1 Day 1 only, nivolumab will be followed by a single dose of ipilimumab 1 mg/kg IV over 30 minutes. Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm B: Platinum Doublet Chemo n=213 Participants Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm C: Nivo 360 mg + Platinum Doublet Chemo n=179 Participants Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Total n=505 Participants Total of all reporting groups
Age, Customized < 65	62 Participants n=37 Participants	99 Participants n=56 Participants	93 Participants n=82 Participants	254 Participants n=31 Participants
Age, Customized >= 65 AND < 75	40 Participants n=37 Participants	96 Participants n=56 Participants	75 Participants n=82 Participants	211 Participants n=31 Participants
Age, Customized >= 75 AND < 85	11 Participants n=37 Participants	17 Participants n=56 Participants	11 Participants n=82 Participants	39 Participants n=31 Participants
Age, Customized >= 85	0 Participants n=37 Participants	1 Participants n=56 Participants	0 Participants n=82 Participants	1 Participants n=31 Participants
Sex: Female, Male Female	40 Participants n=37 Participants	65 Participants n=56 Participants	51 Participants n=82 Participants	156 Participants n=31 Participants
Sex: Female, Male Male	73 Participants n=37 Participants	148 Participants n=56 Participants	128 Participants n=82 Participants	349 Participants n=31 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	2 Participants n=37 Participants	5 Participants n=56 Participants	0 Participants n=82 Participants	7 Participants n=31 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	53 Participants n=37 Participants	105 Participants n=56 Participants	100 Participants n=82 Participants	258 Participants n=31 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	58 Participants n=37 Participants	103 Participants n=56 Participants	79 Participants n=82 Participants	240 Participants n=31 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=37 Participants	0 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants
Race (NIH/OMB) Asian	41 Participants n=37 Participants	96 Participants n=56 Participants	86 Participants n=82 Participants	223 Participants n=31 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=37 Participants	0 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants
Race (NIH/OMB) Black or African American	4 Participants n=37 Participants	5 Participants n=56 Participants	4 Participants n=82 Participants	13 Participants n=31 Participants
Race (NIH/OMB) White	64 Participants n=37 Participants	108 Participants n=56 Participants	89 Participants n=82 Participants	261 Participants n=31 Participants
Race (NIH/OMB) More than one race	0 Participants n=37 Participants	0 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants
Race (NIH/OMB) Unknown or Not Reported	4 Participants n=37 Participants	4 Participants n=56 Participants	0 Participants n=82 Participants	8 Participants n=31 Participants

PRIMARY outcome

Timeframe: From randomization to disease progression, reoccurrence, or death due to any cause. (Up to a median of 30 months)

Population: All concurrently randomized participants in Arm C and Arm B

Event-free survival (EFS) is defined as the length of time from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on blinded independent central review (BICR) assessment per response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Outcome measures

Measure	Arm B: Platinum Doublet Chemo n=179 Participants Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm C: Nivo 360 mg + Platinum Doublet Chemo n=179 Participants Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
Event-Free Survival (EFS)	20.80 Months Interval 14.03 to 26.71	31.57 Months Interval 30.16 to Insufficient number of participants with events

PRIMARY outcome

Timeframe: From randomization up to a median of 30 months after randomization.

Population: All concurrently randomized participants in Arm C and Arm B

Pathologic complete response (pCR) rate is defined as the number of randomized participants with absence of residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR).

Outcome measures

Measure	Arm B: Platinum Doublet Chemo n=179 Participants Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm C: Nivo 360 mg + Platinum Doublet Chemo n=179 Participants Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
Pathologic Complete Response (pCR) Rate	4 Participants	43 Participants

SECONDARY outcome

Timeframe: From randomization up to a median of 30 months after randomization.

Population: All concurrently randomized participants in Arm C and Arm B

Major pathologic response (MPR) rate is defined as number of randomized participants with </= 10% residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR). Viable tumors in situ carcinoma should not be included in MPR calculation.

Outcome measures

Measure	Arm B: Platinum Doublet Chemo n=179 Participants Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm C: Nivo 360 mg + Platinum Doublet Chemo n=179 Participants Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
Major Pathologic Response (MPR) Rate	16 Participants	66 Participants

SECONDARY outcome

Timeframe: From randomization to the date of death (Up to approximately 93 months)

Population: All concurrently randomized participants in Arm C and Arm B

Overall survival (OS) is defined as the time between the date of randomization and the date of death. OS will be censored on the last date a participant was known to be alive.

Outcome measures

Measure	Arm B: Platinum Doublet Chemo n=179 Participants Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm C: Nivo 360 mg + Platinum Doublet Chemo n=179 Participants Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
Overall Survival (OS)	73.72 Months Interval 47.34 to Insufficient number of participants with events	NA Months Insufficient number of participants with events

SECONDARY outcome

Timeframe: From randomization to the first date of distant metastasis or the date of death in the absence of distant metastasis (Up to approximately 84 months)

Population: All concurrently randomized participants in Arm C and Arm B

TTDM is defined as the time between the date of randomization and the first date of distant metastasis or the date of death in the absence of distant metastasis. Distant metastasis is defined as any new lesion that is outside of the thorax using blinded independent central review (BICR) according to response evaluation criteria in solid tumors (RECIST) 1.1. Patients who have not developed distant metastasis or died at the time of analysis will be censored on the date of their last evaluable tumor assessment.

Outcome measures

Measure	Arm B: Platinum Doublet Chemo n=179 Participants Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm C: Nivo 360 mg + Platinum Doublet Chemo n=179 Participants Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
Time to Death or Distant Metastases (TTDM)	36.76 Months Interval 24.74 to 56.8	64.66 Months Interval 49.02 to Insufficient number of participants with events

POST_HOC outcome

Timeframe: From randomization to disease progression, reoccurrence, or death due to any cause. (Up to a median of 69 months)

Population: All concurrently randomized participants in Arm C and Arm B

Event-free survival (EFS) is defined as the length of time from randomization to any of the following events: any progression of disease precluding surgery, progression or recurrence disease based on blinded independent central review (BICR) assessment per response evaluation criteria in solid tumors (RECIST) 1.1 after surgery, or death due to any cause. Participants who don't undergo surgery for reason other than progression will be considered to have an event at progression or death. Progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Outcome measures

Measure	Arm B: Platinum Doublet Chemo n=179 Participants Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm C: Nivo 360 mg + Platinum Doublet Chemo n=179 Participants Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
Event-Free Survival (EFS)	21.06 Months Interval 16.53 to 36.76	59.60 Months Interval 31.57 to Insufficient number of participants with events

Adverse Events

Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg

Serious events: 30 serious events

Other events: 102 other events

Deaths: 46 deaths

Arm B: Platinum Doublet Chemo

Serious events: 58 serious events

Other events: 202 other events

Deaths: 105 deaths

Arm C: Nivo 360 mg + Platinum Doublet Chemo

Serious events: 53 serious events

Other events: 160 other events

Deaths: 66 deaths

Serious adverse events

Measure	Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg n=111 participants at risk Participants received nivolumab 3 mg/kg IV over 30 minutes every 2 weeks for up to 3 doses (ie, 6 weeks of treatment; each cycle is 14 days). In Cycle 1 Day 1 only, nivolumab will be followed by a single dose of ipilimumab 1 mg/kg IV over 30 minutes. Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm B: Platinum Doublet Chemo n=208 participants at risk Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm C: Nivo 360 mg + Platinum Doublet Chemo n=176 participants at risk Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
Blood and lymphatic system disorders Anaemia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Blood and lymphatic system disorders Coagulopathy	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	2.9% 6/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	1.7% 3/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Blood and lymphatic system disorders Myelosuppression	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Blood and lymphatic system disorders Neutropenia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.96% 2/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Blood and lymphatic system disorders Pancytopenia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Blood and lymphatic system disorders Sickle cell anaemia with crisis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Cardiac disorders Arrhythmia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Cardiac disorders Arteriosclerosis coronary artery	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Cardiac disorders Atrial fibrillation	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Cardiac disorders Cardiac failure	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Cardiac disorders Cardiac ventricular thrombosis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Cardiac disorders Myocardial infarction	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Cardiac disorders Myocardial ischaemia	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Cardiac disorders Myocarditis	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Cardiac disorders Stress cardiomyopathy	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Endocrine disorders Adrenal insufficiency	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Endocrine disorders Hypophysitis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Endocrine disorders Inappropriate antidiuretic hormone secretion	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Eye disorders Ocular myasthenia	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Colitis	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Constipation	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Diarrhoea	1.8% 2/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.96% 2/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Gastric ulcer	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
General disorders Death	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Haematochezia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Nausea	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Oesophageal perforation	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Vomiting	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	2.3% 4/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
General disorders General physical health deterioration	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
General disorders Malaise	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Hepatobiliary disorders Drug-induced liver injury	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Nervous system disorders Syncope	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Hepatobiliary disorders Hepatitis	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Immune system disorders Anaphylactic reaction	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Immune system disorders Hypersensitivity	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Bacteraemia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Cellulitis	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Empyema	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Enterocolitis infectious	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Gastroenteritis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Infectious pleural effusion	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Influenza	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Klebsiella bacteraemia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Nasopharyngitis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Pleural infection	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Pneumonia	4.5% 5/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	3.8% 8/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	3.4% 6/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Pneumonia aspiration	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Pneumonia bacterial	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Pneumonia influenzal	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Post procedural infection	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Pyelonephritis acute	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Respiratory tract infection	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Sepsis	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Septic shock	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Subcutaneous abscess	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Tuberculosis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Upper respiratory tract infection	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Urinary tract infection	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Wound infection	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Injury, poisoning and procedural complications Cardiac function disturbance postoperative	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Injury, poisoning and procedural complications Overdose	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Injury, poisoning and procedural complications Post procedural complication	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	1.1% 2/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Injury, poisoning and procedural complications Post procedural haematoma	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Injury, poisoning and procedural complications Post procedural haemorrhage	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Injury, poisoning and procedural complications Postoperative delirium	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Injury, poisoning and procedural complications Postoperative respiratory failure	1.8% 2/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Injury, poisoning and procedural complications Postoperative wound complication	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Injury, poisoning and procedural complications Procedural haemorrhage	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Investigations Aspartate aminotransferase increased	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Investigations Blood creatinine increased	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Investigations Glycosylated haemoglobin increased	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Investigations Hepatic enzyme abnormal	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Investigations Transaminases increased	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Metabolism and nutrition disorders Decreased appetite	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.96% 2/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Musculoskeletal and connective tissue disorders Myositis	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant neoplasm progression	1.8% 2/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	2.4% 5/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	1.1% 2/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Renal cancer	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Second primary malignancy	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour pseudoprogression	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Nervous system disorders Carotid artery stenosis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Nervous system disorders Cerebral infarction	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Nervous system disorders Encephalopathy	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Nervous system disorders Immune-mediated myasthenia gravis	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Nervous system disorders Ischaemic stroke	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Nervous system disorders Neuropathy peripheral	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Nervous system disorders Posterior reversible encephalopathy syndrome	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Renal and urinary disorders Acute kidney injury	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.96% 2/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	1.7% 3/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Reproductive system and breast disorders Prostatitis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Atelectasis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Bronchopleural fistula	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.96% 2/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Bronchospasm	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Chylothorax	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Lung opacity	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Pneumonitis	3.6% 4/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Pneumonitis aspiration	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	1.7% 3/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Pulmonary fistula	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.96% 2/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Pulmonary mass	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	1.1% 2/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Skin and subcutaneous tissue disorders Rash	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Vascular disorders Aortic rupture	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Vascular disorders Arterial thrombosis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Vascular disorders Deep vein thrombosis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Vascular disorders Embolism	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	1.1% 2/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Vascular disorders Hypotension	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Vascular disorders Iliac artery occlusion	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Vascular disorders Subclavian vein thrombosis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Vascular disorders Superficial vein thrombosis	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.57% 1/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.

Other adverse events

Measure	Arm A: Nivo 3 mg/kg + Ipi 1 mg/kg n=111 participants at risk Participants received nivolumab 3 mg/kg IV over 30 minutes every 2 weeks for up to 3 doses (ie, 6 weeks of treatment; each cycle is 14 days). In Cycle 1 Day 1 only, nivolumab will be followed by a single dose of ipilimumab 1 mg/kg IV over 30 minutes. Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm B: Platinum Doublet Chemo n=208 participants at risk Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.	Arm C: Nivo 360 mg + Platinum Doublet Chemo n=176 participants at risk Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days). Following definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.
Blood and lymphatic system disorders Anaemia	8.1% 9/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	37.5% 78/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	35.2% 62/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Blood and lymphatic system disorders Leukopenia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	8.2% 17/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	10.2% 18/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Blood and lymphatic system disorders Neutropenia	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	18.8% 39/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	18.2% 32/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	8.2% 17/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	2.8% 5/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Cardiac disorders Atrial fibrillation	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	3.8% 8/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.1% 9/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Ear and labyrinth disorders Tinnitus	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	8.2% 17/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	3.4% 6/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Endocrine disorders Hyperthyroidism	6.3% 7/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.00% 0/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	4.0% 7/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Endocrine disorders Hypothyroidism	9.9% 11/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	0.48% 1/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	1.1% 2/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
General disorders Fatigue	21.6% 24/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	18.8% 39/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	17.0% 30/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Constipation	21.6% 24/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	35.1% 73/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	35.8% 63/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Diarrhoea	16.2% 18/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	16.3% 34/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	11.9% 21/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Nausea	21.6% 24/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	50.5% 105/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	41.5% 73/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Stomatitis	3.6% 4/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.8% 12/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	3.4% 6/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Gastrointestinal disorders Vomiting	9.0% 10/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	14.4% 30/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	11.4% 20/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
General disorders Asthenia	11.7% 13/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	13.0% 27/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	10.8% 19/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
General disorders Malaise	2.7% 3/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	12.5% 26/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	15.3% 27/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
General disorders Non-cardiac chest pain	3.6% 4/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.8% 12/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	4.0% 7/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
General disorders Oedema peripheral	3.6% 4/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.3% 11/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	3.4% 6/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
General disorders Pain	7.2% 8/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	13.9% 29/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	10.2% 18/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
General disorders Pyrexia	16.2% 18/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	11.1% 23/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	11.4% 20/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Pneumonia	2.7% 3/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	6.7% 14/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	8.5% 15/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Infections and infestations Upper respiratory tract infection	3.6% 4/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	3.8% 8/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.1% 9/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Injury, poisoning and procedural complications Incision site pain	9.0% 10/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	2.9% 6/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	1.7% 3/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Injury, poisoning and procedural complications Procedural pain	10.8% 12/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.8% 12/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	9.7% 17/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Injury, poisoning and procedural complications Wound complication	3.6% 4/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	7.2% 15/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	8.0% 14/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Investigations Alanine aminotransferase increased	6.3% 7/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	8.7% 18/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	7.4% 13/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Investigations Aspartate aminotransferase increased	2.7% 3/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	6.7% 14/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	2.3% 4/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Investigations Blood creatinine increased	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	6.7% 14/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	8.5% 15/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Investigations Neutrophil count decreased	6.3% 7/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	22.1% 46/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	15.9% 28/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Investigations Platelet count decreased	1.8% 2/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	6.7% 14/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	10.2% 18/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Investigations Weight decreased	2.7% 3/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.8% 12/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.7% 10/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Investigations White blood cell count decreased	3.6% 4/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	12.5% 26/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	9.1% 16/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Metabolism and nutrition disorders Decreased appetite	16.2% 18/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	25.5% 53/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	26.7% 47/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Metabolism and nutrition disorders Hyperglycaemia	5.4% 6/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	3.4% 7/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	2.8% 5/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Metabolism and nutrition disorders Hypoalbuminaemia	1.8% 2/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	4.3% 9/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.7% 10/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	8.7% 18/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.7% 10/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Metabolism and nutrition disorders Hyponatraemia	1.8% 2/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	7.7% 16/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	4.5% 8/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Musculoskeletal and connective tissue disorders Arthralgia	10.8% 12/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	6.2% 13/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	8.0% 14/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Musculoskeletal and connective tissue disorders Back pain	5.4% 6/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.8% 12/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	4.5% 8/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Nervous system disorders Dizziness	9.0% 10/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	4.8% 10/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.1% 9/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Nervous system disorders Dysgeusia	6.3% 7/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	4.8% 10/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	2.3% 4/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Nervous system disorders Headache	7.2% 8/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	7.7% 16/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	4.5% 8/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Nervous system disorders Neuropathy peripheral	0.00% 0/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	1.9% 4/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	5.7% 10/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Psychiatric disorders Anxiety	7.2% 8/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	3.8% 8/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	2.3% 4/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Psychiatric disorders Insomnia	7.2% 8/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	7.2% 15/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	8.0% 14/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Cough	13.5% 15/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	14.9% 31/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	12.5% 22/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Dyspnoea	14.4% 16/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	8.7% 18/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	8.5% 15/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Hiccups	2.7% 3/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	14.4% 30/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	10.2% 18/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Respiratory, thoracic and mediastinal disorders Productive cough	5.4% 6/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	4.8% 10/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	1.1% 2/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Skin and subcutaneous tissue disorders Alopecia	0.90% 1/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	13.5% 28/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	11.4% 20/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Skin and subcutaneous tissue disorders Pruritus	15.3% 17/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	3.4% 7/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	7.4% 13/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.
Skin and subcutaneous tissue disorders Rash	15.3% 17/111 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	3.4% 7/208 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.	14.2% 25/176 • All-cause mortality was assessed from randomization to study completion (up to approximately 93 months). SAEs and Other AEs were assessed from first dose to 100days after the last dose of neoadjuvant therapy or 90 days after surgery, whichever is longer, and 30 days after the last dose of adjuvant therapy (up to approximately 5.5 months). The number at Risk for All-Cause Mortality represents all Randomized Participants (One participant randomized to Arm A (nivo+ipi) received the wrong treatment of chemo. This participant is counted in Arm B (chemo) safety analyses). The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.

Additional Information

Bristol-Myers Squibb Study Director

Bristol-Myers Squibb

Phone: Please email

Email: Clinical.Trials@bms.com

Results disclosure agreements

• Principal investigator is a sponsor employee Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.
• Publication restrictions are in place

Restriction type: OTHER